pharmaphorum

DECEMBER 1, 2021

Thomas Turi, chief scientific officer at Nexelis, tells us how a biomarker-led R&D approach is transforming drug development in disease areas like non-alcoholic steatohepatitis (NASH) and cancer, and provides best-practice tips for companies looking to harness this approach.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Drug Development 52

pharmaphorum

JUNE 17, 2025

Skip to main content Tuesday 17 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Diabetes 89

Diabetes Pharmaceutical Companies Pharmaceutical Companies Biosimilars 89

Pharmaceutical Technology

JUNE 19, 2025

Both modalities have emerged as the most used platform technologies in developing oligonucleotide-based drugs for CNS disorders since 2020. Can pharma tariffs “Make America Manufacture Again”? ASOs accounted for more than half ($3.54 billion), while siRNAs made up more than a third ($2.51 billion) of these deals.

Communication 52

Communication Hospitals Pharmaceutical Manufacturing Packaging 52

pharmaphorum

JUNE 10, 2025

Skip to main content Tuesday 10 June 2025 twitter linkedin facebook rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Diabetes 95

Diabetes Pharmaceutical Companies Pharmaceutical Companies Biosimilars 95

pharmaphorum

JUNE 8, 2021

“But we are glad to see the situation for innovative drugs in Asian markets improving, especially in mainland China and South Korea, where policies, societies and regulations are actively promoting innovation. “At At the same time, lots of people with experience at multinational pharmaceutical companies have chosen to return home.

Chemotherapy 105

Chemotherapy Pharmaceutical Companies Pharmaceutical Companies Immunity 105

Pharmaceutical Technology

JUNE 25, 2025

By GlobalData Learn more about Strategic Intelligence In light of the approvals of Leqembi and Kisunla, large pharmaceutical companies are increasingly investing in Alzheimer’s disease through high-value acquisitions. Can pharma tariffs “Make America Manufacture Again”? Stay proactive with real-time data and expert analysis.

Packaging 59

Packaging Biosimilars Communication Hospitals 59

Pharmaceutical Technology

JUNE 25, 2025

Other countries from outside the EU and international organisations such as pharmaceutical companies will be able to apply to join HealthData@EU for secondary use in March 2034. Can pharma tariffs “Make America Manufacture Again”?

Communication 52

Communication Hospitals Packaging Pharmaceutical Companies 52

pharmaphorum

JUNE 17, 2025

billion takeover bid for Verve Therapeutics, upgrading a collaboration between the two companies that dates back to 2023. billion takeover bid for Verve Therapeutics, upgrading a collaboration between the two companies that dates back to 2023.

Diabetes 59

Diabetes Pharmaceutical Companies Pharmaceutical Companies Biosimilars 59

pharmaphorum

JUNE 24, 2025

Skip to main content Tuesday 24 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Diabetes 52

Diabetes Pharmaceutical Companies Pharmaceutical Companies Drug Development 52

pharmaphorum

OCTOBER 28, 2021

Access to medicines attracts a great deal of interest from patients, clinicians, and the public and there have been significant advances in drug development in recent years which looks set to continue. How the combination treatment challenge impacts patients and how we are working together to solve it.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Drug Development 52

pharmaphorum

OCTOBER 1, 2021

Pharma is embracing patient centricity in drug development. Replicate a drug’s EU market success in the US requires pharma to be fully aware of the ever-changing national and state requirements and regulations, says Two Labs’ Howard Miller. Navigating the patient maze – pharma’s evolving challenge.

Communication 52

Communication Pharmaceutical Companies Pharmaceutical Companies Drug Development 52

Viseven

AUGUST 7, 2024

This allows pharmaceutical companies to maintain their brand voice and facilitates information sharing. Many aspiring medical writers falsely believe they should market their services only to pharmaceutical and medical device companies. All their claims are well-researched and supported by data.

Communication 52

Communication Documentation Pharmaceutical Companies Pharmaceutical Companies 52

Pharmaceutical Technology

JUNE 25, 2025

Vaccine R&D stagnation likely Although ACIP recommendations are separate from the US Food and Drug Administration (FDA)’s approvals, national immunisation recommendation provides a key pillar on which to guide pipeline development for a pharmaceutical company. Can pharma tariffs “Make America Manufacture Again”?

Vaccines 115

Vaccines Hospitals Packaging Communication 115

Pharmaceutical Technology

JUNE 27, 2025

It feels like in the US, pharmaceutical companies are capitalising on people’s frustration and desperation to lose weight.” Unintended compounded price point Compounded drugs are custom-made and unbranded medications that contain the same active ingredient as a marketed drug, such as semaglutide or tirzepatide via a prescription.

Drug Pricing 59

Drug Pricing Compounding Packaging Communication 59